Literature DB >> 30532876

A case of ventricular asystole without escape rhythm 4 days after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy with drug-resistant paroxysmal atrial fibrillation.

Mitsunori Ohtsubo1, Hiroto Sakai1, Hisashi Kon1, Hideyuki Takano1.   

Abstract

A 42-year-old man with a more than 10-year history of hypertrophic obstructive cardiomyopathy, but no history of heart failure or syncope, had left ventricular outflow tract pressure gradient (LVOT-PG) of 50-80 mmHg on Doppler echocardiography. In June 2010, he experienced general malaise on effort, and LVOT-PG increased to 124 mmHg. Two months later, he suffered a transient ischemic attack, complicated with atrial fibrillation (AF). He underwent cardiac defibrillation and was prescribed amiodarone, but the arrhythmia recurred easily. Therefore, percutaneous transluminal septal myocardial ablation (PTSMA) was performed to prevent AF. The procedure entailed transient complete atrioventricular block (CAVB), which was resolved after a few hours. Four days later, CAVB recurred and advanced to fatal ventricular asystole without escape rhythm. The patient was resuscitated instantaneously and recovered without brain damage. Finally, a DDD permanent pacemaker was implanted 10 days after the procedure. Except for conduction problems, his cardiac condition was good after PTSMA, as paroxysmal AF disappeared and LVOT-PG was markedly decreased. CAVB is a well-known complication of PTSMA, but fatal ventricular asystole several days after the procedure is rare. Intensive care is required after PTSMA implementation.

Entities:  

Keywords:  Complete atrioventricular block; Hypertrophic obstructive cardiomyopathy; Percutaneous transluminal septal myocardial ablation; Ventricular asystole

Year:  2011        PMID: 30532876      PMCID: PMC6265096          DOI: 10.1016/j.jccase.2011.07.002

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  9 in total

1.  Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients.

Authors:  C Knight; A S Kurbaan; H Seggewiss; M Henein; M Gunning; D Harrington; D Fassbender; U Gleichmann; U Sigwart
Journal:  Circulation       Date:  1997-04-15       Impact factor: 29.690

2.  Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy.

Authors:  N M Lakkis; S F Nagueh; N S Kleiman; D Killip; Z X He; M S Verani; R Roberts; W H Spencer
Journal:  Circulation       Date:  1998-10-27       Impact factor: 29.690

3.  Percutaneous septal ablation: a new treatment for hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss
Journal:  Neth Heart J       Date:  2001-11       Impact factor: 2.380

4.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients.

Authors:  L Faber; A Meissner; P Ziemssen; H Seggewiss
Journal:  Heart       Date:  2000-03       Impact factor: 5.994

5.  Percutaneous transluminal septal myocardial ablation (PTSMA) for symptomatic patients with hypertrophic obstructive cardiomyopathy: first experience.

Authors:  J M Ten Berg; H H D Idzerda; W Jaarsma
Journal:  Neth Heart J       Date:  2001-11       Impact factor: 2.380

6.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.

Authors:  U Sigwart
Journal:  Lancet       Date:  1995-07-22       Impact factor: 79.321

7.  Impact of percutaneous transluminal septal myocardial ablation on refractory paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Yusuke Hosokawa; Hitoshi Takano; Tadaaki Ohno; Morimasa Takayama; Teruo Takano
Journal:  Angiology       Date:  2008-04-02       Impact factor: 3.619

8.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography.

Authors:  L Faber; H Seggewiss; U Gleichmann
Journal:  Circulation       Date:  1998-12-01       Impact factor: 29.690

9.  Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy.

Authors:  Su Min Chang; Sherif F Nagueh; William H Spencer; Nasser M Lakkis
Journal:  J Am Coll Cardiol       Date:  2003-07-16       Impact factor: 24.094

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.